ArticleJournal of gastroenterology and hepatology2026

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Takanori Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.